nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—MAOB—Alzheimer's disease	0.262	0.565	CbGaD
Amphetamine—SLC6A4—Alzheimer's disease	0.118	0.255	CbGaD
Amphetamine—CYP2A6—Memantine—Alzheimer's disease	0.104	0.342	CbGbCtD
Amphetamine—DRD2—Memantine—Alzheimer's disease	0.0906	0.298	CbGbCtD
Amphetamine—CYP2D6—Alzheimer's disease	0.0832	0.18	CbGaD
Amphetamine—CYP2D6—Rivastigmine—Alzheimer's disease	0.0472	0.155	CbGbCtD
Amphetamine—CYP2D6—Donepezil—Alzheimer's disease	0.0377	0.124	CbGbCtD
Amphetamine—CYP2D6—Galantamine—Alzheimer's disease	0.0243	0.08	CbGbCtD
Amphetamine—CARTPT—telencephalic ventricle—Alzheimer's disease	0.0114	0.185	CbGeAlD
Amphetamine—SLC6A2—locus ceruleus—Alzheimer's disease	0.00496	0.0808	CbGeAlD
Amphetamine—SLC18A2—telencephalic ventricle—Alzheimer's disease	0.00386	0.0628	CbGeAlD
Amphetamine—CARTPT—forebrain—Alzheimer's disease	0.00296	0.0483	CbGeAlD
Amphetamine—SLC6A3—telencephalic ventricle—Alzheimer's disease	0.00292	0.0475	CbGeAlD
Amphetamine—CARTPT—telencephalon—Alzheimer's disease	0.00273	0.0444	CbGeAlD
Amphetamine—Dysphoria—Donepezil—Alzheimer's disease	0.00237	0.0243	CcSEcCtD
Amphetamine—DRD2—telencephalic ventricle—Alzheimer's disease	0.00215	0.0349	CbGeAlD
Amphetamine—Stomach ache—Rivastigmine—Alzheimer's disease	0.00214	0.022	CcSEcCtD
Amphetamine—Sudden death—Memantine—Alzheimer's disease	0.00182	0.0186	CcSEcCtD
Amphetamine—TAAR1—nervous system—Alzheimer's disease	0.00161	0.0262	CbGeAlD
Amphetamine—CARTPT—nervous system—Alzheimer's disease	0.00161	0.0262	CbGeAlD
Amphetamine—TAAR1—central nervous system—Alzheimer's disease	0.00155	0.0252	CbGeAlD
Amphetamine—CARTPT—central nervous system—Alzheimer's disease	0.00155	0.0252	CbGeAlD
Amphetamine—CARTPT—cerebellum—Alzheimer's disease	0.00151	0.0247	CbGeAlD
Amphetamine—Tooth disorder—Memantine—Alzheimer's disease	0.00143	0.0147	CcSEcCtD
Amphetamine—Tooth disorder—Rivastigmine—Alzheimer's disease	0.0014	0.0144	CcSEcCtD
Amphetamine—CARTPT—brain—Alzheimer's disease	0.00123	0.02	CbGeAlD
Amphetamine—Accidental injury—Donepezil—Alzheimer's disease	0.00116	0.0119	CcSEcCtD
Amphetamine—Speech disorder—Memantine—Alzheimer's disease	0.00108	0.0111	CcSEcCtD
Amphetamine—Speech disorder—Rivastigmine—Alzheimer's disease	0.00106	0.0108	CcSEcCtD
Amphetamine—Accidental injury—Memantine—Alzheimer's disease	0.00105	0.0108	CcSEcCtD
Amphetamine—Injury—Galantamine—Alzheimer's disease	0.00104	0.0107	CcSEcCtD
Amphetamine—SLC18A2—forebrain—Alzheimer's disease	0.00101	0.0164	CbGeAlD
Amphetamine—Viral infection—Rivastigmine—Alzheimer's disease	0.00101	0.0103	CcSEcCtD
Amphetamine—Dyskinesia—Memantine—Alzheimer's disease	0.000989	0.0101	CcSEcCtD
Amphetamine—Cerebrovascular accident—Galantamine—Alzheimer's disease	0.000979	0.01	CcSEcCtD
Amphetamine—Dyskinesia—Rivastigmine—Alzheimer's disease	0.000968	0.00993	CcSEcCtD
Amphetamine—Disturbance in sexual arousal—Galantamine—Alzheimer's disease	0.000951	0.00976	CcSEcCtD
Amphetamine—SLC18A2—telencephalon—Alzheimer's disease	0.000926	0.0151	CbGeAlD
Amphetamine—Euphoric mood—Donepezil—Alzheimer's disease	0.00088	0.00903	CcSEcCtD
Amphetamine—Abdominal pain upper—Galantamine—Alzheimer's disease	0.000876	0.00899	CcSEcCtD
Amphetamine—SLC22A3—embryo—Alzheimer's disease	0.000811	0.0132	CbGeAlD
Amphetamine—Injury—Donepezil—Alzheimer's disease	0.000809	0.0083	CcSEcCtD
Amphetamine—Libido decreased—Donepezil—Alzheimer's disease	0.000801	0.00822	CcSEcCtD
Amphetamine—SLC6A3—forebrain—Alzheimer's disease	0.000762	0.0124	CbGeAlD
Amphetamine—Cerebrovascular accident—Donepezil—Alzheimer's disease	0.000758	0.00778	CcSEcCtD
Amphetamine—MAOB—embryo—Alzheimer's disease	0.000751	0.0122	CbGeAlD
Amphetamine—Weight decreased—Galantamine—Alzheimer's disease	0.00075	0.00769	CcSEcCtD
Amphetamine—Disturbance in sexual arousal—Donepezil—Alzheimer's disease	0.000737	0.00757	CcSEcCtD
Amphetamine—Depression—Galantamine—Alzheimer's disease	0.000737	0.00756	CcSEcCtD
Amphetamine—Injury—Memantine—Alzheimer's disease	0.000734	0.00753	CcSEcCtD
Amphetamine—Affect lability—Donepezil—Alzheimer's disease	0.000732	0.00751	CcSEcCtD
Amphetamine—Libido decreased—Memantine—Alzheimer's disease	0.000728	0.00747	CcSEcCtD
Amphetamine—Psychotic disorder—Donepezil—Alzheimer's disease	0.000726	0.00745	CcSEcCtD
Amphetamine—Urinary tract infection—Galantamine—Alzheimer's disease	0.000718	0.00737	CcSEcCtD
Amphetamine—Injury—Rivastigmine—Alzheimer's disease	0.000718	0.00737	CcSEcCtD
Amphetamine—Libido decreased—Rivastigmine—Alzheimer's disease	0.000712	0.0073	CcSEcCtD
Amphetamine—Irritability—Donepezil—Alzheimer's disease	0.000709	0.00728	CcSEcCtD
Amphetamine—Mood swings—Donepezil—Alzheimer's disease	0.000704	0.00722	CcSEcCtD
Amphetamine—SLC6A3—telencephalon—Alzheimer's disease	0.000701	0.0114	CbGeAlD
Amphetamine—SLC6A4—forebrain—Alzheimer's disease	0.000698	0.0114	CbGeAlD
Amphetamine—Cerebrovascular accident—Memantine—Alzheimer's disease	0.000689	0.00707	CcSEcCtD
Amphetamine—Abdominal pain upper—Donepezil—Alzheimer's disease	0.000679	0.00697	CcSEcCtD
Amphetamine—Cerebrovascular accident—Rivastigmine—Alzheimer's disease	0.000674	0.00691	CcSEcCtD
Amphetamine—Disturbance in sexual arousal—Memantine—Alzheimer's disease	0.000669	0.00687	CcSEcCtD
Amphetamine—Affect lability—Memantine—Alzheimer's disease	0.000664	0.00682	CcSEcCtD
Amphetamine—MAOB—forebrain—Alzheimer's disease	0.000664	0.0108	CbGeAlD
Amphetamine—Psychotic disorder—Memantine—Alzheimer's disease	0.000659	0.00676	CcSEcCtD
Amphetamine—Disturbance in sexual arousal—Rivastigmine—Alzheimer's disease	0.000655	0.00672	CcSEcCtD
Amphetamine—Affect lability—Rivastigmine—Alzheimer's disease	0.00065	0.00667	CcSEcCtD
Amphetamine—Psychotic disorder—Rivastigmine—Alzheimer's disease	0.000645	0.00662	CcSEcCtD
Amphetamine—Irritability—Memantine—Alzheimer's disease	0.000644	0.00661	CcSEcCtD
Amphetamine—SLC6A4—telencephalon—Alzheimer's disease	0.000642	0.0105	CbGeAlD
Amphetamine—Mood swings—Memantine—Alzheimer's disease	0.000639	0.00656	CcSEcCtD
Amphetamine—Mood swings—Rivastigmine—Alzheimer's disease	0.000625	0.00642	CcSEcCtD
Amphetamine—SLC6A2—forebrain—Alzheimer's disease	0.000615	0.01	CbGeAlD
Amphetamine—MAOB—telencephalon—Alzheimer's disease	0.00061	0.00994	CbGeAlD
Amphetamine—Abdominal pain upper—Rivastigmine—Alzheimer's disease	0.000603	0.00619	CcSEcCtD
Amphetamine—Weight decreased—Donepezil—Alzheimer's disease	0.000581	0.00596	CcSEcCtD
Amphetamine—Depression—Donepezil—Alzheimer's disease	0.000571	0.00586	CcSEcCtD
Amphetamine—Tension—Galantamine—Alzheimer's disease	0.000567	0.00582	CcSEcCtD
Amphetamine—SLC6A2—telencephalon—Alzheimer's disease	0.000565	0.0092	CbGeAlD
Amphetamine—Acute coronary syndrome—Donepezil—Alzheimer's disease	0.000565	0.00579	CcSEcCtD
Amphetamine—Myocardial infarction—Donepezil—Alzheimer's disease	0.000561	0.00576	CcSEcCtD
Amphetamine—Nervousness—Galantamine—Alzheimer's disease	0.000561	0.00576	CcSEcCtD
Amphetamine—DRD2—forebrain—Alzheimer's disease	0.00056	0.00912	CbGeAlD
Amphetamine—Urinary tract infection—Donepezil—Alzheimer's disease	0.000557	0.00571	CcSEcCtD
Amphetamine—Sweating—Donepezil—Alzheimer's disease	0.000549	0.00563	CcSEcCtD
Amphetamine—SLC18A2—nervous system—Alzheimer's disease	0.000547	0.0089	CbGeAlD
Amphetamine—Tremor—Galantamine—Alzheimer's disease	0.000541	0.00555	CcSEcCtD
Amphetamine—Erectile dysfunction—Memantine—Alzheimer's disease	0.000537	0.00551	CcSEcCtD
Amphetamine—Agitation—Galantamine—Alzheimer's disease	0.000531	0.00545	CcSEcCtD
Amphetamine—Weight decreased—Memantine—Alzheimer's disease	0.000528	0.00541	CcSEcCtD
Amphetamine—SLC18A2—central nervous system—Alzheimer's disease	0.000527	0.00857	CbGeAlD
Amphetamine—Erectile dysfunction—Rivastigmine—Alzheimer's disease	0.000526	0.00539	CcSEcCtD
Amphetamine—Photosensitivity reaction—Rivastigmine—Alzheimer's disease	0.000521	0.00534	CcSEcCtD
Amphetamine—Depression—Memantine—Alzheimer's disease	0.000519	0.00532	CcSEcCtD
Amphetamine—Weight decreased—Rivastigmine—Alzheimer's disease	0.000516	0.0053	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Memantine—Alzheimer's disease	0.000516	0.00529	CcSEcCtD
Amphetamine—DRD2—telencephalon—Alzheimer's disease	0.000515	0.00839	CbGeAlD
Amphetamine—SLC18A2—cerebellum—Alzheimer's disease	0.000515	0.00838	CbGeAlD
Amphetamine—Acute coronary syndrome—Memantine—Alzheimer's disease	0.000513	0.00526	CcSEcCtD
Amphetamine—Palpitations—Galantamine—Alzheimer's disease	0.00051	0.00524	CcSEcCtD
Amphetamine—Myocardial infarction—Memantine—Alzheimer's disease	0.00051	0.00523	CcSEcCtD
Amphetamine—Depression—Rivastigmine—Alzheimer's disease	0.000507	0.00521	CcSEcCtD
Amphetamine—Urinary tract infection—Memantine—Alzheimer's disease	0.000505	0.00519	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Rivastigmine—Alzheimer's disease	0.000504	0.00518	CcSEcCtD
Amphetamine—Acute coronary syndrome—Rivastigmine—Alzheimer's disease	0.000502	0.00515	CcSEcCtD
Amphetamine—Convulsion—Galantamine—Alzheimer's disease	0.0005	0.00513	CcSEcCtD
Amphetamine—Myocardial infarction—Rivastigmine—Alzheimer's disease	0.000499	0.00512	CcSEcCtD
Amphetamine—Hypertension—Galantamine—Alzheimer's disease	0.000499	0.00512	CcSEcCtD
Amphetamine—Urinary tract infection—Rivastigmine—Alzheimer's disease	0.000495	0.00507	CcSEcCtD
Amphetamine—Chest pain—Galantamine—Alzheimer's disease	0.000492	0.00505	CcSEcCtD
Amphetamine—Anxiety—Galantamine—Alzheimer's disease	0.00049	0.00503	CcSEcCtD
Amphetamine—Sweating—Rivastigmine—Alzheimer's disease	0.000488	0.005	CcSEcCtD
Amphetamine—Dry mouth—Galantamine—Alzheimer's disease	0.000481	0.00493	CcSEcCtD
Amphetamine—Tachycardia—Galantamine—Alzheimer's disease	0.00046	0.00472	CcSEcCtD
Amphetamine—Pargyline—MAOB—Alzheimer's disease	0.00046	0.122	CrCbGaD
Amphetamine—CYP2A6—cerebellum—Alzheimer's disease	0.00046	0.00748	CbGeAlD
Amphetamine—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000456	0.00468	CcSEcCtD
Amphetamine—Anorexia—Galantamine—Alzheimer's disease	0.000449	0.00461	CcSEcCtD
Amphetamine—Erythema multiforme—Memantine—Alzheimer's disease	0.000441	0.00453	CcSEcCtD
Amphetamine—Tension—Donepezil—Alzheimer's disease	0.000439	0.00451	CcSEcCtD
Amphetamine—Nervousness—Donepezil—Alzheimer's disease	0.000435	0.00446	CcSEcCtD
Amphetamine—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000432	0.00443	CcSEcCtD
Amphetamine—Insomnia—Galantamine—Alzheimer's disease	0.000426	0.00437	CcSEcCtD
Amphetamine—Tremor—Donepezil—Alzheimer's disease	0.000419	0.0043	CcSEcCtD
Amphetamine—Somnolence—Galantamine—Alzheimer's disease	0.000419	0.0043	CcSEcCtD
Amphetamine—SLC18A2—brain—Alzheimer's disease	0.000418	0.00681	CbGeAlD
Amphetamine—Dyspepsia—Galantamine—Alzheimer's disease	0.000415	0.00426	CcSEcCtD
Amphetamine—SLC6A3—nervous system—Alzheimer's disease	0.000414	0.00673	CbGeAlD
Amphetamine—Agitation—Donepezil—Alzheimer's disease	0.000411	0.00422	CcSEcCtD
Amphetamine—Decreased appetite—Galantamine—Alzheimer's disease	0.00041	0.0042	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000407	0.00418	CcSEcCtD
Amphetamine—Fatigue—Galantamine—Alzheimer's disease	0.000406	0.00417	CcSEcCtD
Amphetamine—Constipation—Galantamine—Alzheimer's disease	0.000403	0.00414	CcSEcCtD
Amphetamine—Tension—Memantine—Alzheimer's disease	0.000399	0.00409	CcSEcCtD
Amphetamine—SLC6A3—central nervous system—Alzheimer's disease	0.000398	0.00648	CbGeAlD
Amphetamine—Nervousness—Memantine—Alzheimer's disease	0.000395	0.00405	CcSEcCtD
Amphetamine—Tension—Rivastigmine—Alzheimer's disease	0.00039	0.004	CcSEcCtD
Amphetamine—SLC22A3—nervous system—Alzheimer's disease	0.000389	0.00634	CbGeAlD
Amphetamine—SLC6A3—cerebellum—Alzheimer's disease	0.000389	0.00634	CbGeAlD
Amphetamine—Convulsion—Donepezil—Alzheimer's disease	0.000388	0.00398	CcSEcCtD
Amphetamine—Hypertension—Donepezil—Alzheimer's disease	0.000386	0.00397	CcSEcCtD
Amphetamine—Nervousness—Rivastigmine—Alzheimer's disease	0.000386	0.00396	CcSEcCtD
Amphetamine—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.000385	0.00395	CcSEcCtD
Amphetamine—Chest pain—Donepezil—Alzheimer's disease	0.000381	0.00391	CcSEcCtD
Amphetamine—Tremor—Memantine—Alzheimer's disease	0.000381	0.00391	CcSEcCtD
Amphetamine—Anxiety—Donepezil—Alzheimer's disease	0.00038	0.0039	CcSEcCtD
Amphetamine—SLC6A4—nervous system—Alzheimer's disease	0.000379	0.00617	CbGeAlD
Amphetamine—SLC22A3—central nervous system—Alzheimer's disease	0.000375	0.0061	CbGeAlD
Amphetamine—Agitation—Memantine—Alzheimer's disease	0.000373	0.00383	CcSEcCtD
Amphetamine—CYP2A6—brain—Alzheimer's disease	0.000373	0.00608	CbGeAlD
Amphetamine—Dry mouth—Donepezil—Alzheimer's disease	0.000373	0.00382	CcSEcCtD
Amphetamine—Abdominal pain—Galantamine—Alzheimer's disease	0.000373	0.00382	CcSEcCtD
Amphetamine—Body temperature increased—Galantamine—Alzheimer's disease	0.000373	0.00382	CcSEcCtD
Amphetamine—Tremor—Rivastigmine—Alzheimer's disease	0.000372	0.00382	CcSEcCtD
Amphetamine—Agitation—Rivastigmine—Alzheimer's disease	0.000365	0.00375	CcSEcCtD
Amphetamine—SLC6A4—central nervous system—Alzheimer's disease	0.000365	0.00594	CbGeAlD
Amphetamine—Infection—Donepezil—Alzheimer's disease	0.000363	0.00372	CcSEcCtD
Amphetamine—MAOB—nervous system—Alzheimer's disease	0.00036	0.00587	CbGeAlD
Amphetamine—Palpitations—Memantine—Alzheimer's disease	0.000359	0.00369	CcSEcCtD
Amphetamine—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000353	0.00362	CcSEcCtD
Amphetamine—Convulsion—Memantine—Alzheimer's disease	0.000352	0.00361	CcSEcCtD
Amphetamine—Palpitations—Rivastigmine—Alzheimer's disease	0.000351	0.0036	CcSEcCtD
Amphetamine—Hypertension—Memantine—Alzheimer's disease	0.000351	0.0036	CcSEcCtD
Amphetamine—Anorexia—Donepezil—Alzheimer's disease	0.000348	0.00357	CcSEcCtD
Amphetamine—Hypersensitivity—Galantamine—Alzheimer's disease	0.000347	0.00356	CcSEcCtD
Amphetamine—MAOB—central nervous system—Alzheimer's disease	0.000347	0.00565	CbGeAlD
Amphetamine—Chest pain—Memantine—Alzheimer's disease	0.000346	0.00355	CcSEcCtD
Amphetamine—Anxiety—Memantine—Alzheimer's disease	0.000345	0.00354	CcSEcCtD
Amphetamine—Convulsion—Rivastigmine—Alzheimer's disease	0.000344	0.00353	CcSEcCtD
Amphetamine—Hypertension—Rivastigmine—Alzheimer's disease	0.000343	0.00352	CcSEcCtD
Amphetamine—MAOB—cerebellum—Alzheimer's disease	0.000339	0.00552	CbGeAlD
Amphetamine—Chest pain—Rivastigmine—Alzheimer's disease	0.000338	0.00347	CcSEcCtD
Amphetamine—Dry mouth—Memantine—Alzheimer's disease	0.000338	0.00347	CcSEcCtD
Amphetamine—Asthenia—Galantamine—Alzheimer's disease	0.000338	0.00347	CcSEcCtD
Amphetamine—Anxiety—Rivastigmine—Alzheimer's disease	0.000337	0.00346	CcSEcCtD
Amphetamine—CYP2D6—forebrain—Alzheimer's disease	0.000337	0.00548	CbGeAlD
Amphetamine—SLC6A2—nervous system—Alzheimer's disease	0.000334	0.00543	CbGeAlD
Amphetamine—Dry mouth—Rivastigmine—Alzheimer's disease	0.000331	0.0034	CcSEcCtD
Amphetamine—Insomnia—Donepezil—Alzheimer's disease	0.00033	0.00339	CcSEcCtD
Amphetamine—Infection—Memantine—Alzheimer's disease	0.00033	0.00338	CcSEcCtD
Amphetamine—Dyspnoea—Donepezil—Alzheimer's disease	0.000326	0.00334	CcSEcCtD
Amphetamine—Somnolence—Donepezil—Alzheimer's disease	0.000325	0.00333	CcSEcCtD
Amphetamine—Tachycardia—Memantine—Alzheimer's disease	0.000324	0.00332	CcSEcCtD
Amphetamine—Diarrhoea—Galantamine—Alzheimer's disease	0.000323	0.00331	CcSEcCtD
Amphetamine—Infection—Rivastigmine—Alzheimer's disease	0.000322	0.00331	CcSEcCtD
Amphetamine—Dyspepsia—Donepezil—Alzheimer's disease	0.000322	0.0033	CcSEcCtD
Amphetamine—SLC6A2—central nervous system—Alzheimer's disease	0.000321	0.00523	CbGeAlD
Amphetamine—Hyperhidrosis—Memantine—Alzheimer's disease	0.000321	0.00329	CcSEcCtD
Amphetamine—Decreased appetite—Donepezil—Alzheimer's disease	0.000318	0.00326	CcSEcCtD
Amphetamine—Tachycardia—Rivastigmine—Alzheimer's disease	0.000317	0.00325	CcSEcCtD
Amphetamine—SLC6A3—brain—Alzheimer's disease	0.000316	0.00515	CbGeAlD
Amphetamine—Anorexia—Memantine—Alzheimer's disease	0.000316	0.00324	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000315	0.00324	CcSEcCtD
Amphetamine—Fatigue—Donepezil—Alzheimer's disease	0.000315	0.00323	CcSEcCtD
Amphetamine—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000314	0.00322	CcSEcCtD
Amphetamine—Constipation—Donepezil—Alzheimer's disease	0.000312	0.00321	CcSEcCtD
Amphetamine—Lacosamide—CA4—Alzheimer's disease	0.000312	0.0826	CrCbGaD
Amphetamine—Dizziness—Galantamine—Alzheimer's disease	0.000312	0.0032	CcSEcCtD
Amphetamine—CYP2D6—telencephalon—Alzheimer's disease	0.00031	0.00504	CbGeAlD
Amphetamine—Anorexia—Rivastigmine—Alzheimer's disease	0.000309	0.00317	CcSEcCtD
Amphetamine—Ephedrine—ACHE—Alzheimer's disease	0.000306	0.081	CrCbGaD
Amphetamine—DRD2—nervous system—Alzheimer's disease	0.000304	0.00495	CbGeAlD
Amphetamine—Insomnia—Memantine—Alzheimer's disease	0.0003	0.00308	CcSEcCtD
Amphetamine—Vomiting—Galantamine—Alzheimer's disease	0.0003	0.00308	CcSEcCtD
Amphetamine—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000299	0.00306	CcSEcCtD
Amphetamine—SLC22A3—brain—Alzheimer's disease	0.000298	0.00485	CbGeAlD
Amphetamine—Rash—Galantamine—Alzheimer's disease	0.000297	0.00305	CcSEcCtD
Amphetamine—Dermatitis—Galantamine—Alzheimer's disease	0.000297	0.00305	CcSEcCtD
Amphetamine—Tranylcypromine—MAOB—Alzheimer's disease	0.000296	0.0784	CrCbGaD
Amphetamine—Dyspnoea—Memantine—Alzheimer's disease	0.000296	0.00303	CcSEcCtD
Amphetamine—Headache—Galantamine—Alzheimer's disease	0.000295	0.00303	CcSEcCtD
Amphetamine—Somnolence—Memantine—Alzheimer's disease	0.000295	0.00303	CcSEcCtD
Amphetamine—Insomnia—Rivastigmine—Alzheimer's disease	0.000293	0.00301	CcSEcCtD
Amphetamine—DRD2—central nervous system—Alzheimer's disease	0.000293	0.00477	CbGeAlD
Amphetamine—Dyspepsia—Memantine—Alzheimer's disease	0.000292	0.003	CcSEcCtD
Amphetamine—Urticaria—Donepezil—Alzheimer's disease	0.00029	0.00298	CcSEcCtD
Amphetamine—SLC6A4—brain—Alzheimer's disease	0.00029	0.00472	CbGeAlD
Amphetamine—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000289	0.00297	CcSEcCtD
Amphetamine—Abdominal pain—Donepezil—Alzheimer's disease	0.000289	0.00296	CcSEcCtD
Amphetamine—Body temperature increased—Donepezil—Alzheimer's disease	0.000289	0.00296	CcSEcCtD
Amphetamine—Somnolence—Rivastigmine—Alzheimer's disease	0.000288	0.00296	CcSEcCtD
Amphetamine—Decreased appetite—Memantine—Alzheimer's disease	0.000288	0.00296	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000286	0.00294	CcSEcCtD
Amphetamine—DRD2—cerebellum—Alzheimer's disease	0.000286	0.00466	CbGeAlD
Amphetamine—Fatigue—Memantine—Alzheimer's disease	0.000286	0.00293	CcSEcCtD
Amphetamine—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000286	0.00293	CcSEcCtD
Amphetamine—Constipation—Memantine—Alzheimer's disease	0.000284	0.00291	CcSEcCtD
Amphetamine—Decreased appetite—Rivastigmine—Alzheimer's disease	0.000282	0.00289	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.00028	0.00287	CcSEcCtD
Amphetamine—Nausea—Galantamine—Alzheimer's disease	0.00028	0.00287	CcSEcCtD
Amphetamine—Fatigue—Rivastigmine—Alzheimer's disease	0.00028	0.00287	CcSEcCtD
Amphetamine—Constipation—Rivastigmine—Alzheimer's disease	0.000277	0.00285	CcSEcCtD
Amphetamine—MAOB—brain—Alzheimer's disease	0.000275	0.00448	CbGeAlD
Amphetamine—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000271	0.00278	CcSEcCtD
Amphetamine—Hypersensitivity—Donepezil—Alzheimer's disease	0.000269	0.00276	CcSEcCtD
Amphetamine—SLC22A5—cerebellum—Alzheimer's disease	0.000266	0.00434	CbGeAlD
Amphetamine—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000265	0.00272	CcSEcCtD
Amphetamine—Urticaria—Memantine—Alzheimer's disease	0.000263	0.0027	CcSEcCtD
Amphetamine—Body temperature increased—Memantine—Alzheimer's disease	0.000262	0.00269	CcSEcCtD
Amphetamine—Abdominal pain—Memantine—Alzheimer's disease	0.000262	0.00269	CcSEcCtD
Amphetamine—Asthenia—Donepezil—Alzheimer's disease	0.000262	0.00269	CcSEcCtD
Amphetamine—Urticaria—Rivastigmine—Alzheimer's disease	0.000258	0.00264	CcSEcCtD
Amphetamine—Body temperature increased—Rivastigmine—Alzheimer's disease	0.000256	0.00263	CcSEcCtD
Amphetamine—Abdominal pain—Rivastigmine—Alzheimer's disease	0.000256	0.00263	CcSEcCtD
Amphetamine—SLC6A2—brain—Alzheimer's disease	0.000255	0.00415	CbGeAlD
Amphetamine—Diarrhoea—Donepezil—Alzheimer's disease	0.00025	0.00256	CcSEcCtD
Amphetamine—Phentermine—MAOB—Alzheimer's disease	0.000248	0.0657	CrCbGaD
Amphetamine—Hypersensitivity—Memantine—Alzheimer's disease	0.000244	0.00251	CcSEcCtD
Amphetamine—Dizziness—Donepezil—Alzheimer's disease	0.000242	0.00248	CcSEcCtD
Amphetamine—Hypersensitivity—Rivastigmine—Alzheimer's disease	0.000239	0.00245	CcSEcCtD
Amphetamine—Asthenia—Memantine—Alzheimer's disease	0.000238	0.00244	CcSEcCtD
Amphetamine—Asthenia—Rivastigmine—Alzheimer's disease	0.000233	0.00239	CcSEcCtD
Amphetamine—DRD2—brain—Alzheimer's disease	0.000232	0.00378	CbGeAlD
Amphetamine—Vomiting—Donepezil—Alzheimer's disease	0.000232	0.00238	CcSEcCtD
Amphetamine—Rash—Donepezil—Alzheimer's disease	0.00023	0.00236	CcSEcCtD
Amphetamine—Dermatitis—Donepezil—Alzheimer's disease	0.00023	0.00236	CcSEcCtD
Amphetamine—Selegiline—MAOB—Alzheimer's disease	0.00023	0.0608	CrCbGaD
Amphetamine—Headache—Donepezil—Alzheimer's disease	0.000229	0.00235	CcSEcCtD
Amphetamine—Diarrhoea—Memantine—Alzheimer's disease	0.000227	0.00233	CcSEcCtD
Amphetamine—Diarrhoea—Rivastigmine—Alzheimer's disease	0.000222	0.00228	CcSEcCtD
Amphetamine—Dizziness—Memantine—Alzheimer's disease	0.000219	0.00225	CcSEcCtD
Amphetamine—Nausea—Donepezil—Alzheimer's disease	0.000217	0.00223	CcSEcCtD
Amphetamine—SLC22A5—brain—Alzheimer's disease	0.000216	0.00352	CbGeAlD
Amphetamine—Dizziness—Rivastigmine—Alzheimer's disease	0.000215	0.0022	CcSEcCtD
Amphetamine—Vomiting—Memantine—Alzheimer's disease	0.000211	0.00216	CcSEcCtD
Amphetamine—Rash—Memantine—Alzheimer's disease	0.000209	0.00215	CcSEcCtD
Amphetamine—Dermatitis—Memantine—Alzheimer's disease	0.000209	0.00214	CcSEcCtD
Amphetamine—Headache—Memantine—Alzheimer's disease	0.000208	0.00213	CcSEcCtD
Amphetamine—Vomiting—Rivastigmine—Alzheimer's disease	0.000206	0.00212	CcSEcCtD
Amphetamine—Rash—Rivastigmine—Alzheimer's disease	0.000205	0.0021	CcSEcCtD
Amphetamine—Dermatitis—Rivastigmine—Alzheimer's disease	0.000204	0.0021	CcSEcCtD
Amphetamine—Headache—Rivastigmine—Alzheimer's disease	0.000203	0.00209	CcSEcCtD
Amphetamine—Phenelzine—MAOB—Alzheimer's disease	0.000202	0.0536	CrCbGaD
Amphetamine—Nausea—Memantine—Alzheimer's disease	0.000197	0.00202	CcSEcCtD
Amphetamine—Nausea—Rivastigmine—Alzheimer's disease	0.000193	0.00198	CcSEcCtD
Amphetamine—CYP2D6—nervous system—Alzheimer's disease	0.000183	0.00298	CbGeAlD
Amphetamine—Ephedrine—BCHE—Alzheimer's disease	0.00018	0.0476	CrCbGaD
Amphetamine—Methamphetamine—MAOB—Alzheimer's disease	0.000177	0.0468	CrCbGaD
Amphetamine—CYP2D6—central nervous system—Alzheimer's disease	0.000176	0.00286	CbGeAlD
Amphetamine—CYP2D6—cerebellum—Alzheimer's disease	0.000172	0.0028	CbGeAlD
Amphetamine—CYP2D6—brain—Alzheimer's disease	0.00014	0.00227	CbGeAlD
Amphetamine—Pseudoephedrine—TNF—Alzheimer's disease	0.000132	0.035	CrCbGaD
Amphetamine—Nateglinide—PPARG—Alzheimer's disease	0.00013	0.0344	CrCbGaD
Amphetamine—Phenformin—CYP2D6—Alzheimer's disease	0.000115	0.0305	CrCbGaD
Amphetamine—Phentermine—SLC6A4—Alzheimer's disease	0.000112	0.0297	CrCbGaD
Amphetamine—Pseudoephedrine—SLC6A4—Alzheimer's disease	0.000106	0.0282	CrCbGaD
Amphetamine—Nateglinide—PTGS1—Alzheimer's disease	9.59e-05	0.0254	CrCbGaD
Amphetamine—Tranylcypromine—CYP2D6—Alzheimer's disease	9.41e-05	0.0249	CrCbGaD
Amphetamine—Methamphetamine—SLC6A4—Alzheimer's disease	8e-05	0.0212	CrCbGaD
Amphetamine—Phentermine—CYP2D6—Alzheimer's disease	7.89e-05	0.0209	CrCbGaD
Amphetamine—Benzyl alcohol—CYP2D6—Alzheimer's disease	7.61e-05	0.0201	CrCbGaD
Amphetamine—Dextroamphetamine—CYP2D6—Alzheimer's disease	7.52e-05	0.0199	CrCbGaD
Amphetamine—Pseudoephedrine—CYP2D6—Alzheimer's disease	7.48e-05	0.0198	CrCbGaD
Amphetamine—Selegiline—CYP2D6—Alzheimer's disease	7.3e-05	0.0193	CrCbGaD
Amphetamine—Nateglinide—CYP2D6—Alzheimer's disease	6.52e-05	0.0173	CrCbGaD
Amphetamine—Methamphetamine—CYP2D6—Alzheimer's disease	5.62e-05	0.0149	CrCbGaD
Amphetamine—DRD2—GPCR ligand binding—APP—Alzheimer's disease	2.31e-05	0.000331	CbGpPWpGaD
Amphetamine—DRD2—GPCRs, Class A Rhodopsin-like—HTR2A—Alzheimer's disease	2.29e-05	0.000329	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—PPARG—Alzheimer's disease	2.27e-05	0.000325	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—GSK3B—Alzheimer's disease	2.25e-05	0.000323	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1R—Alzheimer's disease	2.25e-05	0.000322	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLD3—Alzheimer's disease	2.25e-05	0.000322	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—TPI1—Alzheimer's disease	2.24e-05	0.000321	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CHAT—Alzheimer's disease	2.24e-05	0.000321	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—CREB1—Alzheimer's disease	2.24e-05	0.00032	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CDK5—Alzheimer's disease	2.22e-05	0.000318	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—LPL—Alzheimer's disease	2.16e-05	0.000309	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HSD17B10—Alzheimer's disease	2.15e-05	0.000309	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MAOB—Alzheimer's disease	2.15e-05	0.000308	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—CREB1—Alzheimer's disease	2.14e-05	0.000307	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR6—Alzheimer's disease	2.14e-05	0.000307	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MEF2C—Alzheimer's disease	2.14e-05	0.000306	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PRKCG—Alzheimer's disease	2.1e-05	0.000301	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP46A1—Alzheimer's disease	2.07e-05	0.000297	CbGpPWpGaD
Amphetamine—SLC6A3—NRF2 pathway—TGFB1—Alzheimer's disease	2.07e-05	0.000297	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—GAPDH—Alzheimer's disease	2.07e-05	0.000296	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ACHE—Alzheimer's disease	2.05e-05	0.000294	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NGF—Alzheimer's disease	2.04e-05	0.000293	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—INPP5D—Alzheimer's disease	2.03e-05	0.000291	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—Alzheimer's disease	2.01e-05	0.000288	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ND1—Alzheimer's disease	2e-05	0.000287	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—A2M—Alzheimer's disease	2e-05	0.000286	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCR5—Alzheimer's disease	1.99e-05	0.000285	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	1.97e-05	0.000283	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Alzheimer's disease	1.96e-05	0.000282	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GAL—Alzheimer's disease	1.96e-05	0.00028	CbGpPWpGaD
Amphetamine—SLC6A4—SIDS Susceptibility Pathways—IL6—Alzheimer's disease	1.95e-05	0.000279	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HTR2A—Alzheimer's disease	1.94e-05	0.000279	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ENO1—Alzheimer's disease	1.93e-05	0.000276	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS1—Alzheimer's disease	1.93e-05	0.000276	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CYP2D6—Alzheimer's disease	1.89e-05	0.000271	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CALM1—Alzheimer's disease	1.81e-05	0.00026	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—APOE—Alzheimer's disease	1.81e-05	0.000259	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—LEP—Alzheimer's disease	1.81e-05	0.000259	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CAV1—Alzheimer's disease	1.79e-05	0.000257	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—BCHE—Alzheimer's disease	1.79e-05	0.000256	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GAL—Alzheimer's disease	1.78e-05	0.000255	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—Alzheimer's disease	1.75e-05	0.000251	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—DHCR24—Alzheimer's disease	1.74e-05	0.00025	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ACHE—Alzheimer's disease	1.74e-05	0.000249	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—TP53—Alzheimer's disease	1.74e-05	0.000249	CbGpPWpGaD
Amphetamine—CYP2A6—NRF2 pathway—TGFB1—Alzheimer's disease	1.73e-05	0.000248	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TTR—Alzheimer's disease	1.73e-05	0.000248	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ESR1—Alzheimer's disease	1.73e-05	0.000247	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—F2—Alzheimer's disease	1.72e-05	0.000247	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—INPP5D—Alzheimer's disease	1.72e-05	0.000246	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—F2—Alzheimer's disease	1.7e-05	0.000244	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PLCB1—Alzheimer's disease	1.69e-05	0.000242	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NOTCH1—Alzheimer's disease	1.67e-05	0.000239	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ABCA1—Alzheimer's disease	1.64e-05	0.000235	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS1—Alzheimer's disease	1.63e-05	0.000233	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ENO1—Alzheimer's disease	1.63e-05	0.000233	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP2D6—Alzheimer's disease	1.6e-05	0.000229	CbGpPWpGaD
Amphetamine—SLC6A4—Circadian rythm related genes—IL6—Alzheimer's disease	1.59e-05	0.000228	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—GSK3B—Alzheimer's disease	1.57e-05	0.000224	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CREB1—Alzheimer's disease	1.55e-05	0.000223	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—INS—Alzheimer's disease	1.54e-05	0.000221	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—NPY—Alzheimer's disease	1.54e-05	0.00022	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—Alzheimer's disease	1.54e-05	0.00022	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCR5—Alzheimer's disease	1.53e-05	0.000219	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IAPP—Alzheimer's disease	1.53e-05	0.000219	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—MAPK8—Alzheimer's disease	1.52e-05	0.000218	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCL2—Alzheimer's disease	1.52e-05	0.000218	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—BCHE—Alzheimer's disease	1.51e-05	0.000217	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PYY—Alzheimer's disease	1.51e-05	0.000217	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—HTR2A—Alzheimer's disease	1.5e-05	0.000214	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IGF1—Alzheimer's disease	1.49e-05	0.000214	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CRH—Alzheimer's disease	1.48e-05	0.000212	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CA4—Alzheimer's disease	1.48e-05	0.000212	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PLCB1—Alzheimer's disease	1.43e-05	0.000205	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARGC1A—Alzheimer's disease	1.41e-05	0.000202	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—NPS—Alzheimer's disease	1.41e-05	0.000201	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—HMOX1—Alzheimer's disease	1.4e-05	0.000201	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NPY—Alzheimer's disease	1.4e-05	0.0002	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GAPDHS—Alzheimer's disease	1.39e-05	0.0002	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IAPP—Alzheimer's disease	1.39e-05	0.000199	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCA1—Alzheimer's disease	1.38e-05	0.000198	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NOS3—Alzheimer's disease	1.35e-05	0.000194	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CRH—Alzheimer's disease	1.35e-05	0.000193	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GAB2—Alzheimer's disease	1.34e-05	0.000192	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—SST—Alzheimer's disease	1.34e-05	0.000192	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ATP5A1—Alzheimer's disease	1.32e-05	0.000189	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDK5—Alzheimer's disease	1.31e-05	0.000188	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—F2—Alzheimer's disease	1.31e-05	0.000188	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—APP—Alzheimer's disease	1.31e-05	0.000187	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CHAT—Alzheimer's disease	1.29e-05	0.000185	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—TPI1—Alzheimer's disease	1.29e-05	0.000185	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—LPL—Alzheimer's disease	1.28e-05	0.000184	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NPS—Alzheimer's disease	1.28e-05	0.000183	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PPP3CA—Alzheimer's disease	1.27e-05	0.000182	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR6—Alzheimer's disease	1.26e-05	0.000181	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLD3—Alzheimer's disease	1.26e-05	0.000181	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MAOB—Alzheimer's disease	1.24e-05	0.000177	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PLCB1—Alzheimer's disease	1.23e-05	0.000177	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GAB2—Alzheimer's disease	1.22e-05	0.000174	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—SST—Alzheimer's disease	1.22e-05	0.000174	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HSD17B10—Alzheimer's disease	1.21e-05	0.000173	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARGC1A—Alzheimer's disease	1.19e-05	0.000171	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GAPDH—Alzheimer's disease	1.19e-05	0.000171	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—HMOX1—Alzheimer's disease	1.19e-05	0.00017	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—APP—Alzheimer's disease	1.19e-05	0.00017	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CCL2—Alzheimer's disease	1.17e-05	0.000168	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP46A1—Alzheimer's disease	1.16e-05	0.000167	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—Alzheimer's disease	1.16e-05	0.000166	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—MTHFR—Alzheimer's disease	1.16e-05	0.000166	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—A2M—Alzheimer's disease	1.15e-05	0.000165	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP3—Alzheimer's disease	1.15e-05	0.000165	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PSENEN—Alzheimer's disease	1.15e-05	0.000164	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—Alzheimer's disease	1.14e-05	0.000164	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APH1A—Alzheimer's disease	1.13e-05	0.000162	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ND1—Alzheimer's disease	1.12e-05	0.000161	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PLCB1—Alzheimer's disease	1.12e-05	0.00016	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NCSTN—Alzheimer's disease	1.1e-05	0.000158	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—LPL—Alzheimer's disease	1.09e-05	0.000156	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CALM1—Alzheimer's disease	1.08e-05	0.000155	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—APOE—Alzheimer's disease	1.08e-05	0.000154	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LRP1—Alzheimer's disease	1.07e-05	0.000154	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—CAV1—Alzheimer's disease	1.07e-05	0.000153	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—Alzheimer's disease	1.06e-05	0.000152	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK8—Alzheimer's disease	1.06e-05	0.000151	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—Alzheimer's disease	1.05e-05	0.000151	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GFAP—Alzheimer's disease	1.05e-05	0.00015	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GAL—Alzheimer's disease	1.05e-05	0.00015	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ACHE—Alzheimer's disease	1e-05	0.000143	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—INPP5D—Alzheimer's disease	9.89e-06	0.000142	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—MTHFR—Alzheimer's disease	9.78e-06	0.00014	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—Alzheimer's disease	9.76e-06	0.00014	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—Alzheimer's disease	9.72e-06	0.000139	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ENO1—Alzheimer's disease	9.38e-06	0.000134	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS1—Alzheimer's disease	9.38e-06	0.000134	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARG—Alzheimer's disease	9.38e-06	0.000134	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—A2M—Alzheimer's disease	9.25e-06	0.000133	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—INS—Alzheimer's disease	9.2e-06	0.000132	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP2D6—Alzheimer's disease	9.2e-06	0.000132	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CALM1—Alzheimer's disease	9.14e-06	0.000131	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PRKCG—Alzheimer's disease	9.12e-06	0.000131	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—APOE—Alzheimer's disease	9.11e-06	0.000131	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CAV1—Alzheimer's disease	9.03e-06	0.000129	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PSEN2—Alzheimer's disease	8.96e-06	0.000128	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TGFB1—Alzheimer's disease	8.96e-06	0.000128	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—BCHE—Alzheimer's disease	8.72e-06	0.000125	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CCR5—Alzheimer's disease	8.64e-06	0.000124	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—HTR2A—Alzheimer's disease	8.45e-06	0.000121	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PRKCG—Alzheimer's disease	8.28e-06	0.000119	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NPY—Alzheimer's disease	8.24e-06	0.000118	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLCB1—Alzheimer's disease	8.23e-06	0.000118	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IAPP—Alzheimer's disease	8.19e-06	0.000117	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—NOS3—Alzheimer's disease	8.07e-06	0.000116	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCA1—Alzheimer's disease	7.97e-06	0.000114	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CRH—Alzheimer's disease	7.95e-06	0.000114	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARG—Alzheimer's disease	7.93e-06	0.000114	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCR5—Alzheimer's disease	7.84e-06	0.000112	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—INS—Alzheimer's disease	7.78e-06	0.000112	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HTR2A—Alzheimer's disease	7.68e-06	0.00011	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NPS—Alzheimer's disease	7.54e-06	0.000108	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PPP3CA—Alzheimer's disease	7.5e-06	0.000108	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—F2—Alzheimer's disease	7.41e-06	0.000106	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTK2B—Alzheimer's disease	7.39e-06	0.000106	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—Alzheimer's disease	7.38e-06	0.000106	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—Alzheimer's disease	7.37e-06	0.000106	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—TPI1—Alzheimer's disease	7.24e-06	0.000104	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CHAT—Alzheimer's disease	7.24e-06	0.000104	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SST—Alzheimer's disease	7.19e-06	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GAB2—Alzheimer's disease	7.19e-06	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NTRK2—Alzheimer's disease	7.19e-06	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CALM1—Alzheimer's disease	7.16e-06	0.000103	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GSK3A—Alzheimer's disease	7.13e-06	0.000102	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APP—Alzheimer's disease	7.01e-06	0.0001	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MAOB—Alzheimer's disease	6.94e-06	9.94e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARGC1A—Alzheimer's disease	6.87e-06	9.85e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—HMOX1—Alzheimer's disease	6.84e-06	9.8e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—NOS3—Alzheimer's disease	6.82e-06	9.78e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—Alzheimer's disease	6.75e-06	9.67e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—F2—Alzheimer's disease	6.73e-06	9.65e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GAPDH—Alzheimer's disease	6.68e-06	9.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PLCB1—Alzheimer's disease	6.61e-06	9.48e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—A2M—Alzheimer's disease	6.45e-06	9.25e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—LPL—Alzheimer's disease	6.26e-06	8.97e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—Alzheimer's disease	6.24e-06	8.95e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—Alzheimer's disease	6.23e-06	8.92e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NGFR—Alzheimer's disease	6.17e-06	8.84e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CREB1—Alzheimer's disease	6.13e-06	8.79e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ADAM10—Alzheimer's disease	6.03e-06	8.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CCL2—Alzheimer's disease	6e-06	8.6e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—S100B—Alzheimer's disease	5.7e-06	8.17e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—MTHFR—Alzheimer's disease	5.63e-06	8.07e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ACHE—Alzheimer's disease	5.61e-06	8.04e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—INPP5D—Alzheimer's disease	5.55e-06	7.95e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF2—Alzheimer's disease	5.43e-06	7.78e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CALM1—Alzheimer's disease	5.26e-06	7.54e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS1—Alzheimer's disease	5.26e-06	7.54e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ENO1—Alzheimer's disease	5.26e-06	7.54e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1R—Alzheimer's disease	5.25e-06	7.52e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—APOE—Alzheimer's disease	5.24e-06	7.52e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CAV1—Alzheimer's disease	5.2e-06	7.45e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LPL—Alzheimer's disease	5.03e-06	7.21e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MEF2C—Alzheimer's disease	4.98e-06	7.14e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKCG—Alzheimer's disease	4.89e-06	7.01e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—BCHE—Alzheimer's disease	4.89e-06	7.01e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NGF—Alzheimer's disease	4.76e-06	6.83e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR5—Alzheimer's disease	4.63e-06	6.64e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLCB1—Alzheimer's disease	4.61e-06	6.61e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARG—Alzheimer's disease	4.57e-06	6.55e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HTR2A—Alzheimer's disease	4.53e-06	6.5e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—INS—Alzheimer's disease	4.48e-06	6.42e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCA1—Alzheimer's disease	4.47e-06	6.41e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CALM1—Alzheimer's disease	4.23e-06	6.06e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—LEP—Alzheimer's disease	4.22e-06	6.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APOE—Alzheimer's disease	4.22e-06	6.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CAV1—Alzheimer's disease	4.18e-06	5.99e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ESR1—Alzheimer's disease	4.03e-06	5.77e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—F2—Alzheimer's disease	3.98e-06	5.7e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—NOS3—Alzheimer's disease	3.93e-06	5.63e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOTCH1—Alzheimer's disease	3.89e-06	5.58e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARGC1A—Alzheimer's disease	3.85e-06	5.52e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HMOX1—Alzheimer's disease	3.84e-06	5.5e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—Alzheimer's disease	3.71e-06	5.31e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GSK3B—Alzheimer's disease	3.65e-06	5.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CREB1—Alzheimer's disease	3.62e-06	5.19e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—INS—Alzheimer's disease	3.6e-06	5.16e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—Alzheimer's disease	3.59e-06	5.15e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCL2—Alzheimer's disease	3.54e-06	5.08e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LPL—Alzheimer's disease	3.51e-06	5.03e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1—Alzheimer's disease	3.48e-06	4.99e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTHFR—Alzheimer's disease	3.16e-06	4.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOS3—Alzheimer's disease	3.16e-06	4.53e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—Alzheimer's disease	3.14e-06	4.5e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CALM1—Alzheimer's disease	2.95e-06	4.23e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—APOE—Alzheimer's disease	2.94e-06	4.22e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CAV1—Alzheimer's disease	2.91e-06	4.18e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—Alzheimer's disease	2.71e-06	3.88e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—Alzheimer's disease	2.68e-06	3.84e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—Alzheimer's disease	2.66e-06	3.82e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARG—Alzheimer's disease	2.56e-06	3.67e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—INS—Alzheimer's disease	2.51e-06	3.6e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK8—Alzheimer's disease	2.46e-06	3.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—Alzheimer's disease	2.46e-06	3.52e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—Alzheimer's disease	2.28e-06	3.26e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—NOS3—Alzheimer's disease	2.2e-06	3.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TGFB1—Alzheimer's disease	2.09e-06	2.99e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—Alzheimer's disease	2.02e-06	2.89e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—Alzheimer's disease	1.81e-06	2.59e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—Alzheimer's disease	1.72e-06	2.46e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—Alzheimer's disease	1.57e-06	2.26e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—Alzheimer's disease	1.45e-06	2.08e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—Alzheimer's disease	1.01e-06	1.45e-05	CbGpPWpGaD
